AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30453487
Drug: Control yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control yogurt fermented with Streptococcus thermophiles, Lactobacillus delbrueckii subspecies bulgaricus, and Lactobacillus acidophilus, 80 g daily for 8 weeks
Trial: 26723083
Drug: Anti-thymocyte globulin
RxNorm normalized name: ANTI-THYMOCYTE GLOBULIN
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-thymocyte globulin (ATG) 4.5 mg/kg intravenously over 3 days (0.5 mg/kg 2 days before transplantation, 2.0 mg/kg 1 day before, and 2.0 mg/kg 1 day after)
Trial: 20400411
Drug: Vicriviroc (VCV)
RxNorm normalized name: Vicriviroc
DrugBank: Vicriviroc (DB06652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vicriviroc (VCV) 5, 10, or 15 mg
Trial: 15973115
Drug: 5‐ASA 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA 500 mg suppository (Canasa; Axcan Pharma) BID
Trial: 15973115
Drug: 5‐ASA 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐ASA 1 g at bedtime (HS)
Trial: 14636777
Drug: Antiepileptic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic treatment for transitory cognitive impairment (TCI)
Trial: 8633817
Drug: 3600 mg
RxNorm normalized name: Ascorbic Acid/Calcium 3600 MG-400 MG Oral Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3600 mg saquinavir per day
Trial: 8633817
Drug: 7200 mg
RxNorm normalized name: chymotrypsin 7200 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7200 mg saquinavir per day
Trial: 9259838
Drug: Antithrombin replacement
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin replacement therapy
Trial: 6414283
Drug: Commercial starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial starch blocker
Trial: 31443654
Drug: Single-dose azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-dose azithromycin (20 mg/kg)
Trial: 24708443
Drug: Long-term oral
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term oral corticosteroids (LTOC)
Trial: 21643774
Drug: V0355 (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V0355 (80 mg Fe/day)
Trial: 21643774
Drug: Ferrograd® (105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrograd® (105 mg Fe/day)
Trial: 9808644
Drug: 720 mL/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mL/d of apple juice containing 5 g of gum arabic and pectin (4:1 ratio)
Trial: 9808644
Drug: 720 mL/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mL/d of apple juice containing 9 g of gum arabic and pectin (4:1 ratio)
Trial: 9808644
Drug: 720 mL/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mL/d of apple juice containing 15 g of gum arabic and pectin (4:1 ratio)
Trial: 9808644
Drug: 720 mL/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 720 mL/d of apple juice (control)
Trial: 7631621
Drug: bisoprolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol (2.5 to 10 mg) with 6.25 mg of hydrochlorothiazide (HCTZ)
Trial: 7631621
Drug: amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amlodipine (2.5 to 10 mg)
Trial: 7631621
Drug: enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (5 to 20 mg)
Trial: 7346529
Drug: H-1 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H-1 antagonist hydroxyzine
Trial: 7346529
Drug: H-2 antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: H-2 antagonist cimetidine
Trial: 7346529
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of H-1 and H-2 antagonists
Trial: 31305270
Drug: Pertuzumab (840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab (840 mg loading dose followed by 420 mg maintenance doses every 3 weeks)
Trial: 31305270
Drug: Pertuzumab (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pertuzumab (in combination with trastuzumab)
Trial: 27025843
Drug: IV aminophylline
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV aminophylline (100 mg administered over 30-60 seconds)
Trial: 27025843
Drug: IV caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV caffeine citrate (60 mg infused over 3-5 minutes)
Trial: 19786379
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg lutein/d
Trial: 19786379
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg lutein/d
Trial: 17538165
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus capecitabine (GemCap) - oral capecitabine 650 mg/m2 twice daily on days 1 to 14 plus Gem 1,000 mg/m2 by 30‐minute infusion on days 1 and 8 every 3 weeks
Trial: 17538165
Drug: Gemcitabine (Gem)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (Gem) - 1,000 mg/m2 by 30‐minute infusion weekly for 7 weeks, followed by a 1‐week break, and then weekly for 3 weeks every 4 weeks
Trial: 16566943
Drug: Pulse low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse low doses of methylprednisolone (250 mg given twice IV)
Trial: 14527736
Drug: Second-generation antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antihistamines with combined topical corticosteroid treatment (Group 1)
Trial: 14527736
Drug: Second-generation antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antihistamines without steroid treatment (Group 2)
Trial: 14527736
Drug: Second-generation antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation antihistamines (both groups)
Trial: 10790990
Drug: Stimulants (MPH,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulants (MPH, DEX, pemoline)
Trial: 10790990
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (desipramine, imipramine)
Trial: 10790990
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies (stimulant or nondrug intervention)
Trial: 10790990
Drug: Stimulants vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulants vs. placebo
Trial: 10790990
Drug: Adverse effects
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse effects of drug therapy
Trial: 10790990
Drug: Long-term therapy
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term therapy (> or = 12 weeks)
Trial: 10790990
Drug: Academic performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Academic performance with stimulants
Trial: 8932964
Drug: Standard antidepressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antidepressants (imipramine, fluoxetine, sertraline)
Trial: 1989742
Drug: Local anaesthesia
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthesia combined with light sedation (midazolam 0.1 mg.kg‐1 and alfentanil 0 micrograms.kg‐1)
Trial: 1989742
Drug: General anaesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anaesthesia (propofol 2.5 mg.kg‐1, then 9 mg.kg‐1.hr‐1 and alfentanil 30 micrograms.kg‐1, then 15 micrograms.kg‐1)
Trial: 25560571
Drug: Vildagliptin 100mg
RxNorm normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Vildagliptin 100mg plus metformin
Trial: 23842505
Drug: CR® neuromodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR® neuromodulation therapy
Trial: 20863217
Drug: L-Carnitine 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Carnitine 1000 mg/day for 12 weeks
Trial: 18195111
Drug: ABCC2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABCC2 inhibitor probenecid
Trial: 18195111
Drug: Nonspecific inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonspecific inhibitor verapamil
Trial: 18195111
Drug: ABCB1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ABCB1 inhibitor valspodar (PSC833)
Trial: 12571548
Drug: Placebo-CPAP (CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-CPAP (CPAP administered at ineffective pressure)
Trial: 10596415
Drug: Bifidobacteria (Töpfer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacteria (Töpfer Bifidus) administered via nasogastral tube, initial dosage of 3 times daily 1.25 x 10(8) bifidobacteria on day 2, then 6 times daily 1.25 x 10(8) bifidobacteria on day 3 until day 21
Trial: 28196063
Drug: dCRT (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dCRT (cisplatin 60 mg/m² on day 1 and capecitabine 625 mg/m² bd on days 1-21 for four cycles)
Trial: 28196063
Drug: dCRT+C (dCRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dCRT+C (dCRT plus cetuximab 400 mg/m² on day 1 then 250 mg/m² weekly)
Trial: 26398851
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg for 8 weeks
Trial: 19743466
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA) 1,500mg daily
Trial: 12612146
Drug: Daily supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplement (272 mg vitamin C, 31 mg all‐rac‐alpha‐tocopherol, and 400 micro g folic acid) for 90 days
Trial: 1556292
Drug: Religious Cognitive-Behavioral
RxNorm normalized name: red delicious apple allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Religious Cognitive-Behavioral Therapy (RCT)
Trial: 1556292
Drug: Nonreligious Cognitive-Behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonreligious Cognitive-Behavioral Therapy (NRCT)
Trial: 1556292
Drug: Pastoral Counseling
RxNorm normalized name: castoryl maleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pastoral Counseling Treatment-as-Usual (PCT)
Trial: 31362785
Drug: Local ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local ice cryotherapy (30 min applied twice during 1 day at an 8-h interval)
Trial: 31362785
Drug: Cold CO2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold CO2 (2 min applied twice during 1 day at an 8-h interval)
Trial: 19638799
Drug: Weekly visits
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly visits with WCSs (Group B)
Trial: 16978805
Drug: Formula with
RxNorm normalized name: Stress B Formula with C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula with prebiotic fructo-oligosaccharides at a concentration of 0.4 g/dL
Trial: 2205292
Drug: Vitamin-mineral supplement
RxNorm normalized name: Prenatal Vitamins Oral Tablet [PRENATAL VITAMIN-MINERAL SUPPLEMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-mineral supplement daily for 28 days
Trial: 2205292
Drug: Placebo daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for 28 days
Trial: 26141142
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to antipsychotic monotherapy
Trial: 21612469
Drug: Albuterol followed
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol followed by methacholine (control)
Trial: 16722829
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg primaquine with food
Trial: 16722829
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg primaquine with grapefruit juice
Trial: 16722829
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg primaquine in fasting state
Trial: 8686522
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg morphine and 2.5 mg dehydrobenzperidol (DHB) in 10 ml physiological saline
Trial: 8686522
Drug: 5.0 mg
RxNorm normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.0 mg morphine and 0.1 mg fentanyl in 10 ml physiological saline
Trial: 27857189
Drug: Repaglinide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (oral administration for 8 weeks)
Trial: 27857189
Drug: Repaglinide with
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Repaglinide with KCNQ1 inhibitor
Trial: 24075865
Drug: Laparoscopic cystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic cystectomy by stripping with saline injection (saline group)
Trial: 24075865
Drug: Laparoscopic cystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic cystectomy by stripping with vasopressin injection technique (VIT group)
Trial: 24075865
Drug: Laparoscopic cystectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic cystectomy by stripping without injection (control group)
Trial: 20113339
Drug: Pregabalin 150-600
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150-600 mg/day (dosed twice daily)
Trial: 16271654
Drug: Telephone psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone psychotherapy program (TPP) during maintenance-phase treatment (6-12 months).
Trial: 12499212
Drug: lopinavir/ritonavir 400/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir 400/100 mg BID
Trial: 12499212
Drug: lopinavir/ritonavir 533/133
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir 533/133 mg BID
Trial: 30464128
Drug: Combined thrombus
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined thrombus burden reduction therapy
Trial: 30248056
Drug: Personalized neurofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized neurofeedback cognitive training using the BRAINMEM system, comprising 24 sessions over eight weeks and three monthly booster sessions.
Trial: 24445833
Drug: Inactivated control
RxNorm normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated control trivalent influenza vaccines (TIVs) containing Victoria-lineage B strain
Trial: 24445833
Drug: Inactivated control
RxNorm normalized name: hepatitis A virus strain CR 326F antigen, inactivated Injection [Vaqta]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated control trivalent influenza vaccines (TIVs) containing Yamagata-lineage B strain
Trial: 21916952
Drug: Mandibular overdenture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular overdenture retained by two splinted implants with bar-clip system
Trial: 20082624
Drug: Glipizide controlled-release
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide controlled-release (CR) tablets monotherapy
Trial: 20082624
Drug: Glipizide controlled-release
RxNorm normalized name: glipizide Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide controlled-release (CR) tablets plus acarbose
Trial: 8652324
Drug: modified fluid
RxNorm normalized name: modified fluid gelatin
DrugBank: Succinylated gelatin (DB16568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: modified fluid gelatin (Gel)
Trial: 1647149
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2, day 1)/Etoposide (100 mg/m2, day 1, 3, 5) (PE)
Trial: 1647149
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg/m2, day 1)/Etoposide (100 mg/m2, day 1, 3, 5)/Ifosfamide (2 g/m2, day 1, 2, 3) (PEI)
Trial: 22652942
Drug: Prednisolone, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone, 60 mg/d for 5 days, tapered for 5 days
Trial: 16204002
Drug: Severe leucopenia
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe leucopenia during chemotherapy
Trial: 16204002
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who developed severe leucopenia within the first two cycles of chemotherapy
Trial: 12352809
Drug: Birth dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birth dose of HepB
Trial: 12352809
Drug: No birth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No birth dose of HepB
Trial: 2236929
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 500 micrograms daily
Trial: 2236929
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate 1,000 micrograms daily
Trial: 406627
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg methylphenidate
Trial: 406627
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg methylphenidate (open trial)
Trial: 30379568
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of first-line chemotherapy
Trial: 24638908
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with long‐chain ω‐3 polyunsaturated fatty acids (350 mg DHA + 650 mg EPA)
Trial: 24638908
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with lutein + zeaxanthin (10 mg lutein + 2 mg zeaxanthin)
Trial: 24638908
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of long‐chain ω‐3 fatty acids and lutein + zeaxanthin
Trial: 23651231
Drug: N-acetylcysteine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (800 mg/day)
Trial: 12680858
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (3.7 g n-3 PUFA/day)
Trial: 10887922
Drug: 0.01% all‐trans‐retinoic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01% all‐trans‐retinoic acid (tretinoin) ophthalmic emulsion
Trial: 9197524
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C supplementation (50 or 500 mg/day) for 5 years
Trial: 9197524
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation (0 or 15 mg/day) for 5 years (discontinued after initial recruitment)
Trial: 8110565
Drug: Extradural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extradural morphine 0.75 microgram kg‐1 with an additional dose administered 24 h later (group M)
Trial: 8110565
Drug: Extradural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Extradural fentanyl 2 micrograms kg‐1 followed by continuous extradural infusion of fentanyl 5 micrograms kg‐1 day‐1 (group F)
Trial: 8110565
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of fentanyl 5 micrograms kg‐1 day‐1
Trial: 24412895
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and intra-articular glucocorticosteroid injections with adalimumab
Trial: 24412895
Drug: Methotrexate and
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate and intra-articular glucocorticosteroid injections with placebo
Trial: 8831082
Drug: Prophylactic fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic fresh frozen plasma (20 ml/kg followed by 10 ml/kg after 24 h)
Trial: 8831082
Drug: Control management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control management with a maintenance infusion of 10% dextrose
Trial: 1282183
Drug: 10 or
RxNorm normalized name: K-10 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 or 20 mg nicorandil
Trial: 4040500
Drug: OKY‐1581 (thromboxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY‐1581 (thromboxane A2 synthetase inhibitor); 2-3 micrograms/kg per min for 48 hours
Trial: 4040500
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment with OKY‐1581)